A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Completed

• Conditions: Nephrology

• Registration Number: NCT00189501
• Lead Sponsor: Amgen

Brief Summary

Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters

Detailed Description

Not available

Study Timeline

• Study Start: 2004-12
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-19
• Status Verified: 2007-12
• Last Update Submitted: 2007-12-20
• Last Update Posted: 2007-12-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• 3 month history of Stage 4 or Stage 5 CKD
• A PTH value within 3 months of enrollment
• If relevant, completion of Sensipar® study prior to enrolling in Registry

Exclusion Criteria

• Females who are pregnant or breast feeding

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified